AACR17 audience in Washington DC
Over the last few years we’ve written a tremendous about primary and acquired resistance, both in oncogenic and immunotherapies, as well as on combination strategies for turning non-responders into responders and overcoming acquired resistance that induces clinical relapse.
These concepts were still on display in Washington DC at the 2017 annual meeting for American Association for Cancer Research (AACR), but beyond those obvious top line points, what are the next round of ideas and tools that cancer researchers are focusing on?
Based on numerous presentations, ad hoc discussions, as well as over a dozen one to one interviews we completed with oncology thought leaders, some useful and encouraging trends emerged.
To learn more insights, subscribers can log in
Dr Tom Gajewski (Chicago) and Dr Roberta Zappasodi (MSKCC) in plenary biomarker session
Today, the 2017 annual meeting of the American Association for Cancer Research (AACR) kicked into gear with multiple sessions from early morning until late into the evening (Twitter #AACR17)
Above all else the meeting showcases the value of scientific research, and how improving our knowledge of cancer biology is the foundation upon which new drugs and therapies are developed.
If you know or want to know why cancer can be cured in mice but not in humans, then the AACR annual meeting is the place for you.
In today’s post we’re again providing some end of the day topline commentary on the sessions we attended and the data we heard. We also did several expert interviews that we’ll be writing up in forthcoming weeks.
Subscribers can login to read more